NCT04544111 2025-10-07PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting19 enrolled
NCT03690388 2025-09-25A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyExelixisPhase 3 Active not recruiting187 enrolled 13 charts 1 FDA